QIAGEN has a comprehensive molecular detection technology platform, including QIAcube automated nucleic acid extraction system, QIAstat Dx syndrome detection scheme, and QIAGEN Digital Insights bioinformatics tool. The company continues to expand its product line through independent research and strategic acquisitions such as NeuMoDx and Ingenuity, providing services in areas such as infectious disease detection, tumor companion diagnosis, and agricultural genetic testing. QIAGEN maintains deep cooperation with top medical institutions, research institutes, and pharmaceutical companies worldwide, and its high-quality reagents and automation systems have become the gold standard in molecular biology research.

In 2023, QIAGEN's revenue exceeded $2 billion and maintained strong growth in the fields of infectious disease testing (such as COVID-19, respiratory multi detection) and tumor gene analysis. The company is accelerating the layout of AI driven bioinformatics platforms and portable molecular diagnostic devices, and plans to expand into emerging markets. In 2024, QIAGEN announced partnerships with multiple multinational pharmaceutical companies to develop companion diagnostic products and promote innovative applications of next-generation sequencing (NGS) technology. In the future, QIAGEN will continue to consolidate its leading position in the fields of molecular diagnostics and life sciences through technological innovation and globalization strategies.